Related Experiment Video
Updated: Aug 13, 2026
Differentiation of Functional Osteoclasts from Human Peripheral Blood CD14+ Monocytes
Published on: January 27, 2023
Research progress on the role of CD14 in osteoarthritis
1Department of Orthopedics, Chengdu Fifth People's Hospital, Chengdu, China.
Abstract:
Osteoarthritis (OA) is a complex degenerative disease centered on inflammation and involving multi-cellular cooperation, with a continuously rising global burden. Current therapeutic measures mainly focus on symptom relief, slowing progression, and end-stage joint arthroplasty; no disease-modifying or reversal agent is yet available, underscoring the urgent need to dissect the inflammatory driving mechanisms and identify effective intervention targets. As a pattern recognition receptor, CD14 is highly expressed on synovial macrophages in the OA microenvironment. It recognizes endogenous damage-associated molecular patterns, driving pro-inflammatory responses through both TLR4-dependent (MyD88/NF-κB) and TLR4-independent (NLRP3 inflammasome) pathways. Recent studies have accumulated substantial evidence; clinical samples and animal models consistently show that CD14 deficiency or blockade reduces cartilage damage, synovitis, and pain, while soluble CD14 (sCD14) levels positively correlate with inflammatory cytokines and clinical symptoms, indicating its important role in OA pathogenesis and supporting its value as a biomarker and therapeutic target. This review aims to integrate current evidence, clarify the central pro-inflammatory role of CD14 in OA, and provide a theoretical basis for future precision targeted therapies and biomarker-driven clinical trial designs, thereby advancing the development of diagnostic and therapeutic strategies for OA.
Insights
Cluster of Differentiation 14 (CD14) drives osteoarthritis inflammation via macrophage signaling. Targeting CD14 offers a promising therapeutic strategy for this degenerative joint disease.
Area of Science:
- Immunology
- Rheumatology
- Molecular Biology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with increasing global prevalence.
- Current OA treatments primarily manage symptoms, lacking disease-modifying agents.
- Inflammation and cellular cooperation are central to OA pathogenesis, necessitating new therapeutic targets.
Purpose of the Study:
- To review and integrate evidence on the role of Cluster of Differentiation 14 (CD14) in osteoarthritis.
- To elucidate the pro-inflammatory mechanisms driven by CD14 in the OA microenvironment.
- To establish a theoretical foundation for CD14-targeted therapies and biomarker development in OA.
Main Methods:
- Review of existing clinical and preclinical studies on CD14 in osteoarthritis.
- Analysis of CD14's expression and function on synovial macrophages.
- Examination of CD14's signaling pathways, including TLR4-dependent and independent routes.
Main Results:
- CD14 is highly expressed on macrophages in the OA joint, recognizing damage-associated molecular patterns.
- CD14 activation triggers pro-inflammatory responses via TLR4/MyD88/NF-κB and NLRP3 inflammasome pathways.
- CD14 deficiency or blockade reduces OA pathology, while soluble CD14 (sCD14) correlates with disease severity.
Conclusions:
- CD14 plays a pivotal pro-inflammatory role in osteoarthritis pathogenesis.
- CD14 is a potential biomarker for OA severity and a promising therapeutic target.
- Targeting CD14 pathways may lead to novel precision therapies and improved clinical trial designs for OA.
